Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » AnPac Bio-Medical Nabs $7M Equity Investment for Cancer Early Detection Platform

AnPac Bio-Medical Nabs $7M Equity Investment for Cancer Early Detection Platform

Oct 01, 2020
|
staff reporter

NEW YORK – AnPac Bio-Medical Science said on Thursday that it has signed an agreement with Keystone Capital Partners for a preferred stock investment for an aggregate purchase price of $7 million.

The Shanghai-based firm will use the funding to advance its Cancer Differentiation Analysis (CDA) technology to provide cost-effective, early detection screening and testing of 26 cancers.

According to a prospectus summary filed with the US Securities and Exchange Commission, AnPac will offer 700,000 shares at a price of $10.00 per share to Keystone.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

CMS Letter to Orig3n

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

And After the Test

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

Faster, But Not Fast Enough

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

PLOS Papers on Plasmodium vivax Variation in Ethiopia, Childhood BMI Loci, More

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct
22
Featured Webinar

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

What's Popular?

In Molecular Diagnostics

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. FDA Reissues Emergency Use Authorization for Thermo Fisher Scientific COVID-19 Combo Kit

  3. Fluidigm Shares Rise on Selection of Saliva-Based COVID-19 Assay for Federal Surge Testing

  4. Interdisciplinary NIST Team Claims qPCR Improvements Using Unusual Math Tweaks

    Premium

  5. Tempus Enters Infectious Disease Market With Large-Scale COVID-19 Testing, Data Initiative

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.